

4/18/97

DHHS Working Group

I Health Insurance Discrimination

II. Regulation → Proficiency Testing Focus

FDA / HCFA / CDC not

CDC Proliferation of tests

CF Focus on common ones?

Generic test

HCFA - nothing to add

PTT FDA -

Sig ~~BC~~

Chips

ASO-synth

mult

Reverse dotted blot

Tag man

SSCP

ARMS

CAP/ACMG?

Accreditation body

Proficiency testing not mandated under CLIA

Common lab tests - CF, BRCA1/2, HH

Path 2 or 3, make it sample-based, not tech-based

Newborn screening as a paradigm?

CDC carries out proficiency testing, E HRSA #

CAP/ACMG are limited by need to support the programs,

so role tests won't work

Should small labs be ignored?

Managed care is discriminatory against them

Convene a gathering CDC / HCFA / CAP / ACMG / ...

To define role of PT

When? What size?

Who?

Then Secy can say she took care of this

Dixie charged to develop plan for such a meeting by middle of next week

Analyte validity

Control validity

Clinical utility

36 - An R&D opportunity?

An RFA?

Fakunding, Patricia

From: Francis Collins/DIR/NCHGR [REDACTED]
Sent: Monday, April 14, 1997 7:53 PM
To: patricia
Subject: Materials for next meeting of DHHS Working Group on Gdnetic Testing

[REDACTED]
PROFTEST.GEN

[REDACTED]
SUMMARY.PT

Patti, can you read the attachment? If so, please print out for me.

FC

[REDACTED]

Date: 04/14/97 04:16:33 PM

Subject: Materials for next meeting of DHHS Working Group on Gdnetic Testing

Please find attached two documents that will serve as the basis for the discussion at our meeting on Friday, April 18 from 2:00 to 4:00 in Room 729G. (For those CDC staff members who can't join us in person, we will link you up via Envision.) As you may recall, the principal agenda item for Friday's meeting is the feasibility of developing, as an increment to the CLIA processes for laboratory certification, generic proficiency tests and a proficiency-testing process tailored to the performance of genetic testing.

These attachments have been prepared by CDC in consultation with FDA and HCFA.

This uuencoded part of the message containing the file PROFTEST.GEN has been decoded and converted into an attachment.

This uuencoded part of the message containing the file SUMMARY.PT has been decoded and converted into an attachment.

Final Panel Membership

R. Rodney Howell, M.D.
Conference and Panel Chairperson
Professor and Chairman
Department of Pediatrics
School of Medicine
University of Miami
Miami, Florida

Ingrid Borecki, Ph.D.
Research Associate Professor
Division of Biostatistics
School of Medicine
Washington University
St. Louis, Missouri

Mary E. Davidson, M.S.W., L.C.S.W.-C.
Executive Director
Alliance of Genetic Support Groups
Chevy Chase, Maryland

Ezra C. Davidson, Jr., M.D.
Professor
Department of Obstetrics and Gynecology
King Drew Medical Center and Charles R. Drew
University of Medicine and Science
Los Angeles, California

James P. Evans, M.D., Ph.D.
Clinical Associate Professor, Internal Medicine
University of North Carolina at Chapel Hill
Internist and Geneticist
Carolina Permanente Medical Group
Durham, North Carolina

Bonnie J. Flick, M.D.
Assistant Professor
Departments of Pediatrics and Psychiatry
University of Utah Health Sciences Center
Salt Lake City, Utah

Bradford H. Gray, Ph.D.
Director
Division of Health and Science Policy
New York Academy of Medicine
New York, New York

Mark S. Kamlet, Ph.D.
Dean and H. John Heinz III Professor of
Economics and Public Policy
H. John Heinz School of Public Policy
and Management
Carnegie Mellon University
Pittsburgh, Pennsylvania

Elizabeth R. McAnarney, M.D.
Professor and Chair
Department of Pediatrics
University of Rochester School of Medicine
Rochester, New York

Vicki Michel, M.A., J.D.
Consultant and Mediator in Bioethics and Law
Los Angeles, California
Adjunct Professor
Loyola Law School
Los Angeles, California

Robb E. Moses, M.D.
Chair
Department of Molecular and Medical Genetics
Oregon Health Sciences University
Portland, Oregon

Benjamin F. Payton, Ph.D.
President
Tuskegee University
Tuskegee, Alabama

Owen M. Rennert, M.D.
Professor and Chairman
Department of Pediatrics
Georgetown University Medical Center
Washington, DC

Stephanie C. Smith, M.S.
Genetic Associate
Genetics Services Coordinator
Division of Medical Genetics
Department of Preventive Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Janet K. Williams, Ph.D., R.N.
Associate Professor
College of Nursing
University of Iowa
Iowa City, Iowa

Carrier Screening for Cystic Fibrosis: Costs and Clinical Outcomes

David A. Asch, M.D., M.B.A.

Population-based cystic fibrosis (CF) carrier screening is controversial, in part because genetic screening in the setting of reproductive planning raises important social and ethical issues,¹ and also because even very good tests perform poorly when applied to low prevalence conditions. Furthermore, the application of CF carrier screening is not limited to a single clinical strategy. Many plausible strategies may be constructed using different decision rules for proceeding to further testing or deciding whether to continue a pregnancy.^{2,3} In turn, each strategy yields different clinical and economic outcomes. Thus, the clinical question is not only whether widespread CF carrier screening should be done but also how it should be done.

My colleagues and I used a decision analytic model to define the clinical and economic outcomes expected from several plausible population CF carrier screening strategies. Each clinical strategy evaluated was composed of a plausible arrangement of the following component tests.

Standard Mutation Analysis

Most centers that screen for CF mutations employ a battery of tests targeted at about 5–10 common mutations that in aggregate represent approximately 85 percent of CF alleles (e.g., $\Delta F508$, G542X, G551D, R553X, N1303K, W1282X, $\Delta I507$). Members of a couple are screened in parallel or in series. For example, in one parallel strategy, both partners undergo standard screening and the couple proceeds to prenatal diagnosis with amniocentesis if both partners are found to screen positive. In one sequential strategy, one partner is screened first, the second partner is screened only if the first screens positive, and the couple proceeds to prenatal diagnosis only if both are positive. As an alternative to simple sequential and parallel strategies, we also consider the “couple-screening” strategy proposed by Wald.⁴ DNA samples are collected from both partners (as in parallel strategies), but testing is performed sequentially and results are reported at the level of the couple. For example, couples in which the first partner tests positive and the second partner tests negative are designated “screen negative.”

Expanded Mutation Analysis

Although standard mutation batteries will identify most carriers who can be identified, one might screen for another 20–30 mutations beyond the standard panel. We investigated strategies that use this expanded analysis at the time of the initial screen. In addition, we considered “mixed” strategies that use the expanded analysis only after one parent screens positive on the standard battery—for example, when one and only one partner in a couple screens negative in parallel testing, or when the first partner screens positive in sequential testing. In addition to the alternative of not screening, we investigated 15 unique ways of performing population CF carrier screening. These strategies are listed in Table 1. Several representative tree branches are shown in Figures 1 and 2. All branches end in one of six clinical outcomes that reflect the alternatives of delivery, miscarriage, or abortion and whether the fetus or child is or is not affected with CF.

TABLE 1. List of Clinical Strategies Evaluated			
Parental Sequence	DNA Test Battery	Additional Tests if One and Only One Parent Tests Positive	Strategy
No Screening			A
Parallel	Standard	None	B
		MIE	C
	Expanded	None	D
		MIE	E
	Mixed ^a	None	F
		MIE	G
Sequential	Standard	None	H
		None ^c	I
		MIE	J
	Expanded	None	K
		None ^c	L
		MIE	M
	Mixed ^b	None	N
		None ^c	O
		MIE	P

MIE = 3D microvillar intestinal enzyme analysis.

^a If one and only one partner is negative with the standard battery, rescreen that partner with the expanded battery.

^b If the first partner is positive, screen the second partner with the expanded battery.

^c DNA samples are collected from both parents, but testing is performed sequentially. If both parents screen positive, the *couple* is told they are positive. Otherwise, the *couple* is told they are negative.

Probability Estimates

Probability estimates used in the model were obtained by surveying the literature and consulting experts in obstetrics, genetics, and prenatal diagnosis.

Costs and Resource Use

The base-case analysis is based on costs rather than charges. Cost estimates used in the model are in 1995 dollars. Direct medical costs are included, as are indirect costs, including time lost from work, transportation costs, and the like. Costs were measured from three different perspectives: patient, payer, and society.




FIGURE 1. Three sample clinical strategies (B, C, and N from Table 1) expressed as a decision tree. The tree is read from left to right. The square node indicates a choice to be made among strategies. The round nodes indicate outcomes that result from chance. Each branch ends on a letter indicating a subtree, shown in Figure 2. MIE = 3D Microvillar intestinal enzyme analysis. For an explanation of the three strategies, see Table 1.




FIGURE 2. Two subtrees for Figure 1. Each pregnancy can either be terminated (subtree A) or continued (subtree B). If it is terminated, it might have led to the birth of a child with CF or without CF. If it is continued, it might lead to a miscarriage or to delivery, and in either case might be affected with CF or not.

Clinical Outcomes

Each strategy was evaluated according to its overall cost and the distribution of a hypothetical cohort of 500,000 pregnancies among six clinical outcomes: (1) delivery of a child without CF; (2) delivery of a child with CF; (3) termination of a pregnancy that, if delivered, would have resulted in the birth of a child without CF; (4) termination of a pregnancy that, if delivered, would have resulted in the birth of a child with CF; (5) spontaneous miscarriage of a pregnancy that, if delivered, would have resulted in the birth of a child without CF; (6) miscarriage of a pregnancy that, if delivered, would have resulted in the birth of a child with CF.

Results

Table 2 reports the base-case analysis for all 16 screening strategies applied to a cohort of 500,000 single gestation pregnancies. The table shows the number of pregnancies falling into each of the six clinical outcomes, the total cost from a societal perspective, and a summary cost-effectiveness measure presented as the cost per CF birth avoided relative to the no-screening alternative (strategy A). Compared with no screening, strategy N has the lowest cost per CF birth avoided. In this sequential strategy, the first partner is tested with the standard battery. The second partner is tested with the expanded battery if and only if the first partner's screen is positive. If the second partner is also positive, prenatal diagnosis is performed. This strategy identifies 75 percent of anticipated CF births at a cost of \$367,000 each. This figure assumes that couples who identify a pregnancy at risk will choose to have prenatal diagnosis and termination of affected pregnancies. The cost per CF birth identified is approximately half this figure when couples plan two children. The relative ranking of the various strategies is insensitive to the assumptions in the model, but the cost-effectiveness of each strategy depends critically upon two factors. The cost-effectiveness of carrier screening is significantly reduced if couples decide not to terminate affected pregnancies. The cost-effectiveness of carrier screening is

TABLE 2. Base-Case Analysis for 16 Alternative CF Carrier Screening Strategies

Strategy	CF			Non CF			CF Births Avoided (rel. to A)	Total Cost	Cost Per CF Birth Avoided (rel. to A)
	Births	Abortions	Mis- carriages	Births	Abortions	Mis- carriages			
A	195	0	5	487,305	0	12,495	0	\$1,530,313,000	—
B	57	142	1	487,302	0	12,498	138	\$1,623,710,000	\$676,000
C	8	191	0	486,787	340	12,673	187	\$1,641,185,000	\$594,000
D	40	159	1	487,300	0	12,499	155	\$1,674,352,000	\$930,000
E	6	194	0	486,737	358	12,705	189	\$1,694,522,000	\$867,000
F	39	160	1	487,300	0	12,499	156	\$1,627,544,000	\$625,000
G	8	192	0	486,789	338	12,673	187	\$1,647,277,000	\$626,000
H	57	142	1	487,302	0	12,498	138	\$1,582,937,000	\$381,000
I	57	142	1	487,302	0	12,498	138	\$1,606,318,000	\$550,000
J	33	166	1	487,044	170	12,586	162	\$1,593,161,000	\$387,000
K	40	159	1	487,300	0	12,499	155	\$1,609,657,000	\$512,000
L	40	159	1	487,300	0	12,499	155	\$1,632,701,000	\$661,000
M	23	177	1	487,019	179	12,602	172	\$1,621,475,000	\$530,000
N	49	150	1	487,301	0	12,499	146	\$1,583,972,000	\$367,000
O	49	150	1	487,301	0	12,499	146	\$1,607,352,000	\$527,000
P	32	167	1	487,045	169	12,586	163	\$1,593,807,000	\$391,000

The figures represent the results of a strategy applied to a cohort of 500,000 pregnancies. Strategies are defined in Table 1.

significantly increased if couples plan two or more pregnancies. A central conclusion of this analysis is that the cost-effectiveness of CF carrier screening depends greatly on couples' reproductive plans. CF carrier screening is most cost-effective when it is performed sequentially, when the information is used for more than one pregnancy, and when the intention of the couple is to identify and terminate affected pregnancies.

References

1. Asch DA, Mennuti MT. Evolving policy questions in the use of genetic tests. *IEEE Technol Soc* 1996;15(4):4-11.
2. Asch DA, Hershey JC, Pauly MV, Patton JP, Jedrzejewski MK, Mennuti MT. Genetic screening for reproductive planning: methodologic and conceptual issues in policy analysis. *Am J Public Health* 1996;86:684-90.

3. Asch DA, Patton JP, Hershey JC, Mennuti MT. Reporting the results of cystic fibrosis carrier screening. *Am J Obstet Gynecol* 1993;168:1-6.
4. Wald NJ. Couple screening for cystic fibrosis. *Lancet* 1991;338:1318-9.



DEPARTMENT OF HEALTH & HUMAN SERVICES

JUN 10 1997
Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

June 9, 1997

Francis S. Collins, M.D., Ph.D.
Director
National Human Genome Research Institute
National Institutes of Health
Building 31, Room 4B09
9000 Rockville Pike
Bethesda, MD 20892

*My file - CF Consensus
4/14-16/97*

Dear Dr. Collins:

Enclosed is the final version of the consensus statement on Genetic Testing for Cystic Fibrosis. We plan to have it printed by the Government Printing Office, and as you know, the statement has been submitted to a major medical journal for possible publication.

The printed version of the statement will be mailed to you as soon as it is available.

Sincerely,

William H. Hall
Director of Communications
Office of Medical Applications
of Research

Enclosure

6/3/97 3:00 p.m.



NATIONAL INSTITUTES OF HEALTH
 CONSENSUS DEVELOPMENT CONFERENCE STATEMENT

GENETIC TESTING FOR CYSTIC FIBROSIS

April 14–16, 1997

NIH Consensus Statements are prepared by a nonadvocate, non-Federal panel of experts, based on (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session; (2) questions and statements from conference attendees during open discussion periods that are part of the public session; and (3) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and is not a policy statement of the NIH or the Federal Government.

Abstract

Objective. To provide health care providers, patients, and the general public with a responsible assessment of the optimal practices for genetic testing for cystic fibrosis (CF).

Participants. A non-Federal, nonadvocate, 14-member panel representing the fields of genetics, obstetrics, internal medicine, nursing, social work, epidemiology, pediatrics, psychiatry, genetic counseling, bioethics, health economics, health services research, law, and the public. In addition, 21 experts from these same fields presented data to the panel and a conference audience of 500.

Evidence. The literature was searched through Medline and an extensive bibliography of references was provided to the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience.

Consensus Process. The panel, answering predefined questions, developed its conclusions based on the scientific evidence presented in open forum and the scientific literature. The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference.

Conclusions. Genetic testing for CF should be offered to adults with a positive family history of CF, to partners of people with CF, to couples currently planning a pregnancy, and to couples seeking prenatal testing. The panel does not recommend offering CF genetic testing to the general population or newborn infants. The panel advocates active research to develop improved treatments for people with CF and continued investigation into the understanding of the pathophysiology of the disease. Comprehensive educational programs targeted to health care professionals and the public should be developed using input from people living with CF and their families and from people from diverse racial and ethnic groups. Additionally, genetic counseling services must be accurate and provide balanced information to afford individuals the opportunity to make autonomous decisions. Every attempt should be made to protect individual

rights, genetic and medical privacy rights, and to prevent discrimination and stigmatization. It is essential that the offering of CF carrier testing be phased in over a period of time to ensure that adequate education and appropriate genetic testing and counseling services are available to all persons being tested.

Introduction

Genetic testing is available for a variety of diseases and will soon be available for many more. Furthermore, genetic predispositions to common diseases are becoming known and potentially will affect large segments of the population. This consensus conference considered cystic fibrosis (CF), a well-characterized, serious genetic disease for which testing is becoming available, and a series of recommendations for genetic testing in the population is presented. The analysis and recommendations may prove relevant to genetic testing in other situations.

At the beginning of this decade, a test was developed that could identify individuals who carry the genetic mutation associated with CF. Concerned that this test might be inappropriately or prematurely used, several genetic and health professional organizations issued recommendations on its use. These groups considered the circumstances under which the tests should be offered and the populations that would potentially benefit. Almost all of their recommendations were against using the test for large-scale, population-based screening until more sensitive tests were developed and until more had been learned about the risks and benefits of genetic testing for individuals and their families. Several statements called for additional support for research on the educational, laboratory, counseling, ethical, and cost/benefit issues associated with the delivery of population-based screening for CF. Since that time, new research has yielded a large body of data on these issues.

This conference brought together the research investigators, health care providers, epidemiologists, geneticists, ethicists, and other experts, as well as representatives of the public, to present and discuss the latest data.

Following 1-1/2 days of presentations by experts and audience discussion, an independent, non-Federal consensus panel composed of experts in the fields of genetics, obstetrics, internal medicine, nursing, social work, epidemiology, pediatrics, psychiatry, genetic counseling, bioethics, health economics, health services research, law, and the public weighed the scientific evidence and developed a draft statement in response to the following five key questions:

1. What is the current state of knowledge regarding natural history, epidemiology, genotype-phenotype correlations, treatment, and genetic testing of cystic fibrosis in various populations?
2. What has been learned about genetic testing for cystic fibrosis regarding (public and health professional) knowledge and attitudes, interest and demand, risks and benefits, effectiveness, cost, and impact?
3. Should cystic fibrosis carrier testing be offered to: (1) individuals with a family history of cystic fibrosis; (2) adults in the preconception or prenatal period; and/or (3) the general population?
4. What are the optimal practices for cystic fibrosis genetic testing (setting, timing, and the practices of education, consent, and counseling)?
5. What should be the future directions for research relevant to genetic testing for cystic fibrosis and, more broadly, for research and health policies related to genetic testing?

The primary sponsors of this meeting were the National Human Genome Research Institute and the NIH Office of Medical Applications of Research. The conference was cosponsored by the National Institute of Diabetes and Digestive and Kidney Diseases; the National Heart, Lung, and Blood Institute; the National Institute of Child Health and Human Development; the NIH Office of Rare Diseases; the National Institute of Mental Health; the National Institute of Nursing Research; the NIH Office of Research on Women's Health; the Agency for Health Care Policy and Research; and the Centers for Disease Control and Prevention.

1. **What Is the Current State of Knowledge Regarding Natural History, Epidemiology, Genotype-Phenotype Correlations, Treatment, and Genetic Testing of Cystic Fibrosis in Various Populations?**

CF is a multisystem genetic disease in which defective chloride transport across membranes causes dehydrated secretions. This leads to tenacious mucus in the lungs, to mucus plugs in the pancreas, and to the characteristically high sweat chloride levels. Intelligence and cognitive function are typically normal. A survey in 1995 reported that 35 percent of young adults with CF worked full-time, and almost 90 percent had completed a high school education. More than 25,000 Americans have CF, with approximately 850 individuals newly diagnosed each year. CF is inherited as an autosomal recessive disorder; the responsible gene, the CF transmembrane conductance regulator (CFTR), was mapped to chromosome 7 and identified in 1989.

Natural History

CF has a highly variable presentation and course. Median age at diagnosis is 6–8 months; nearly two-thirds of individuals are diagnosed before 1 year of age. Some individuals have severe pulmonary and/or gastrointestinal disease, whereas others have relatively mild disease with presentation during adolescence and young adulthood. Outcomes range from early death from pulmonary complications to mild atypical disease in the second and third decades, and a rare normal length of life. Even though median survival increased from 18 years in 1976 to 30.1 years in 1995, there has been little life-span extension between 1990 and 1995. Survival has improved, thus far, through aggressive management of pulmonary, pancreatic, and intestinal complications. Despite advances in treatment, there is no cure for CF.

Severity of lung disease is the key to the quality of and length of life. Ninety percent of persons who have CF die from pulmonary complications. Pulmonary function tests, especially forced expiratory volume (FEV₁), are predictive of mortality: when the FEV₁ is ≤ 30 percent, mortality is 50 percent in 2 years. Poor prognosis is related to respiratory complications before 1 year of age, malnutrition, and denial of the condition. Better prognosis is indicated from mild symptoms at diagnosis, pancreatic sufficiency, and atypical presentation. There are suggestions in the literature that early diagnosis and treatment may result in improved growth of young children; however, data are limited about whether early treatment decreases morbidity as measured by hospitalizations and pulmonary function tests and, ultimately, mortality rates.

Treatment

The major goals of traditional treatment of CF are to improve pulmonary, gastrointestinal, and pancreatic outcomes. Pulmonary treatment is focused on physical therapy to decrease obstruction of the airways, antibiotics to decrease colonization by *Staphylococcus aureus* and *Pseudomonas aeruginosa*, and nonsteroidal anti-inflammatory drugs to decrease the inflammatory cascade and resulting tissue damage. Gastrointestinal and pancreatic treatments include high protein–high caloric diets, pancreatic enzymes, and fat-soluble vitamins.

New modalities include the use of inhaled DNase, which breaks down the DNA from neutrophils, and pharmacologic modification of ion transport to loosen secretions. Pharmacologic activation of mutant CFTR protein to stimulate chloride channel activity is being investigated. Double lung transplantation extends life, but is not curative.

There are new findings regarding human beta defensin-1, a factor responsible for innate immunity. The natural bactericidal activity of human beta defensin-1 is inhibited on CF epithelia because of high extracellular sodium chloride, and correction of the sodium chloride concentration of extracellular fluid holds promise for therapy in CF. Finally, although the feasibility of gene therapy is currently under investigation, this potential "cure" is not anticipated in the near future.

Epidemiology

Incidence

CF is one of the most common genetic diseases in Caucasians, with an incidence of about 1 in 3,300. The disease also has a fairly high incidence among Hispanics, 1 in 9,500. CF is a rare disorder in native Africans and native Asians, estimated to occur in less than 1 in 50,000, but higher incidences are observed in American populations of these ethnic groups (1 in 15,300 and 1 in 32,100, respectively), suggesting Caucasian admixture. Recent surveys of some Native-American populations also indicate high incidences: 1 in 3,970 in the Pueblo people, and 1 in 1,580 among the Zuni. These data are summarized in Table 1. The relatively high incidence and concomitant high frequency of carriers motivate the proposal of population-based screening.

CF Mutation Analysis

Since the identification of the gene and the major mutation responsible for CF, more than 600 mutations and DNA sequence variations have been identified in the CFTR gene. The $\Delta F508$ mutation is represented in almost all populations, although its relative frequency varies among different geographic locations. The highest frequency is observed in Caucasian populations, where it accounts for approximately 70 percent of the CF alleles (Table 1). $\Delta F508$ mutation

TABLE 1

Group	Incidence	Carrier Frequency	% $\Delta F508$	% Common Caucasian Alleles	% Group-Specific Alleles	Sensitivity
Caucasians	1/3,300	1/29	70	13	—	80
Hispanics	1/8–9,000	1/46	46	11	—	57
Ashkenazi Jews		1/29	30	67	—	97
Native Americans	1/3,970 1/1,500		0	25	69	94
African-Americans	1/15,300	1/60–65	48	4	23	75
Asian-Americans	1/32,100	1/90	30			30

Source: Modified from Cutting GR. Genetic epidemiology and genotype/phenotype correlations. In: Program and abstracts. NIH Consensus Development Conference on Genetic Testing for Cystic Fibrosis, 1997 Apr 14–16, Bethesda, MD.

accounts for large portions of the alleles in other racial/ethnic groups: 48 percent in African-Americans, 46 percent in Hispanics, and 30 percent in Asian-Americans and Ashkenazi Jews. Some 15–20 other “common” mutations account for 2–15 percent of CF alleles, depending on the ethnic composition of the patient group studied. Most of the remaining mutations are rare.

The proportion of detectable mutations is an important indicator of the utility of a population-screening program. Combining detection of the $\Delta F508$ with other mutations common to specific ethnic groups, it appears that there are several populations for which 90–95 percent sensitivity can now be achieved with the current technology: Ashkenazi Jews, Celtic Bretons, French Canadians from Quebec, and some Native Americans. In Caucasians in the United States, it is feasible to approach 90 percent sensitivity at the current time. The detection rate in African-Americans is about 75 percent. Despite the relatively high incidence in Hispanics, the detectable alleles account for only 57 percent of the CF mutations in this group. The promise appears to be weak in Asian-Americans, at 30 percent sensitivity. Because the remaining mutations are rare, expanding the panel of screened mutations is expected to achieve only marginal gains in sensitivity.

Genotype-Phenotype Correlations

The discovery of the gene has enabled evaluation of specific mutations in relation to the observed clinical heterogeneity. The correlation of genotype with phenotype is substantial for pancreatic function; however, identification of the specific CFTR mutation has not been highly predictive of the severity and course of pulmonary disease, which is the major factor affecting patient quality of life and longevity. Furthermore, there is evidence to suggest a role for modifier genes and environmental factors that are as yet unidentified.

Virtually all males with classic CF have congenital bilateral absence of the vas deferens (CBAVD). However, there is a population of otherwise healthy males with CBAVD who have a high frequency of CF mutations. It appears that more than half of these males have one or two specific mutations, which identifies these genotypes as the most common cause of CBAVD. Some women with these genotypes are normal or develop chronic sinusitis or bronchitis as the extent of their morbidity. It is unclear whether such mildly affected individuals can be reliably identified by their genotype.

Thus, it appears that knowledge of the genotype is as yet of limited value in making predictions about the anticipated course of disease in an individual, although research to identify genotypes associated with relatively mild presentation such as CBAVD may prove useful in informed decisionmaking.

Genetic Testing in Various Populations

Genetic testing has been performed for CF carriers in various racial and ethnic groups, mass and focused screening, and different types of organized medical settings. At this time, there is limited spontaneous public request for this testing. Although testing has not met with enthusiasm, there has been little or no group opposition to offering testing to African-Americans, Asian-Americans, Caucasians, Hispanics, Native Americans, and persons of Jewish ancestry. Most experience has been gained with Caucasians and Ashkenazi Jews, where incidence is highest. Mass screening has resulted in the least response. Pregnant patients appear to be motivated to obtain genetic information. Nonpregnant patients and those with a family history have exhibited only moderate acceptance rates. In the United States, mass screening of newborns has occurred in only two states, Colorado and Wisconsin; otherwise, newborn testing has been limited to those with a family history. The logistics of testing have been successfully implemented in various settings such as HMOs and primary care settings, including fee-for-service settings. With the exception of one fee-for-service setting and the newborn state

programs, all testing has been free of charge. Direct provider recruitment has proven more effective than less personal approaches.

2. What Has Been Learned about Genetic Testing for Cystic Fibrosis Regarding (Public and Health Professional) Knowledge and Attitudes, Interest and Demand, Risks and Benefits, Effectiveness, Cost, and Impact?

Knowledge and Attitudes Toward Cystic Fibrosis and Genetic Testing

As with most genetic diseases, the public's knowledge is very low regarding CF, its genetic basis, and its variable course and prognosis, and understanding of genetic testing is poor. Moreover, among those who have heard of CF, inaccurate impressions often exist, because people are generally not familiar with the progress in treating the disease over the past 40 years. Understanding genetic testing for CF involves learning complex concepts such as test sensitivity, carrier status, patterns of inheritance, risk/probability, and genotype-phenotype correlations. These gaps in the public's genetic knowledge suggest that genetic testing programs must include written informed consent and educational and counseling components.

There are only approximately 2,000 genetic professionals nationally, so implementation of widespread genetic testing must rely heavily on primary care providers and prenatal providers. Some research efforts, however, have shown that many office-based physicians are not interested in participating in genetic testing programs involving CF because of lack of familiarity and concerns with unreimbursed time. Medical practitioners need to become more knowledgeable about genetics, genetic testing, and nondirective counseling as genetic tests become more widely available.

Public Interest and Demand

Notwithstanding the limits of public understanding of genetics and genetically related diseases, prospective parents have enormous interest in the health and well-being of children to be. In an Office of Technology Assessment survey of a decade ago, 83 percent of Americans said they would take a genetic test before having children, if it would tell them whether their children would likely inherit a fatal genetic disease. Many genetic counselors and nurse geneticists report that they are frequently asked about DNA-based CF tests. However, studies have shown that interest in CF genetic testing is limited in the general population, and that agreement to participate in genetic education and testing procedures occurs primarily among pregnant women and persons with positive family histories.

In the prenatal testing context, participation rates have varied widely in studies to date because of variability of methods used, with acceptance of offers for testing ranging from about 50 percent to a high of 78 percent in one HMO population. Participation has been affected by factors relating to convenience, education, cost, views regarding abortion, concerns about the low sensitivity of the test, and the manner of presentation of the testing opportunity. Concerns about confidentiality and insurability are often mentioned in the genetic testing context. There also is evidence of reluctance to engage in carrier testing on the psychological grounds of "not wanting to know," as has occurred in studies where some people with positive family histories chose not to participate.

The reasons for interest in prenatal genetic testing are diverse. Some participants in studies have sought information in anticipation of a decision about pregnancy termination in the case of a fetus with CF. Others wished to know only their carrier status, perhaps to make emotional and practical plans for parenting a child with CF.

Risks

Research has assessed initial concerns among providers of genetic services that genetic testing might have adverse psychological consequences, such as anxiety and depression caused by the difficulty of conveying the uncertainties inherent in genetic testing or the challenge of adjusting to identification as a carrier. The research to date has shown such problems to be transitory; the topic, nevertheless, may warrant additional research incorporating comprehensive psychological assessment tools. The risks of misinformation or misunderstanding highlight the need for a high level of competence in conveying the results and meaning of information derived from genetic testing. Problems retaining complex genetic concepts highlight the need for broad-based public education.

Another concern is the fear that disclosure of genetic test results might affect one's family relationships, employment, educational or other opportunities, or ability to maintain or obtain health insurance. This is a more general problem and needs to be addressed at a broader level to ensure patient access to genetic services and other opportunities without threat of harmful consequences.

Impact and Effectiveness

The effectiveness of genetic testing can be judged in terms of its ability to convey information that patients find useful. The experience to date reports high levels of patient satisfaction after undergoing genetic testing for CF. In the prenatal situation, because of the rarity of the disease, over 99 percent of couples tested receive reassuring information regarding the improbability of having a child with CF.

Several studies have reported significant increases in knowledge of CF among couples who have undergone genetic testing and participated in the educational programs connected with it. Although there was some drop in knowledge after several years, knowledge levels still were higher than in the pretesting period. A decline in understanding has been reported in some research, where a considerable portion of the individuals who were carriers did not retain the meaning of the test results. In some instances, this meant that people incorrectly believed they were no longer at risk for having offspring with CF.

In addition to the educational and psychological benefits of CF testing, the effectiveness of testing can be judged in terms of how the information is used. This is most germane in situations in which a test produced a positive result. Most couples in whom the woman was found to be a carrier chose to have the partner tested as well. The inability of current DNA testing technology to detect all possible mutations and the difficulty in conveying the concept of residual risk temper these positive effects.

Another indicator of impact occurs in the rare instances in which a fetus with CF is identified. In the limited studies to date, most couples with no positive family history in this circumstance choose to terminate the pregnancy. It should be noted that some couples do not undergo final stages of testing because of their intention to continue the pregnancy.

Cost

Assessment of the costs associated with testing, screening, and treatment of CF is challenging because technology and treatment modalities are changing rapidly. Nonetheless, there is general agreement about the magnitude of many of the key cost variables and the likely future direction of change in these costs.

In terms of treatment, options for care for many individuals with CF have expanded over the past decade with implications for the average cost of care. Although the Office of Technology Assessment estimated in 1992, based on 1989 data, that the annual treatment costs were approximately \$10,000 per year per individual with CF, current estimates exceed \$40,000 per year in direct medical costs and \$9,000 per year in ancillary costs. Using a 3 percent discount rate, this implies a net present value of approximately \$800,000 for direct and ancillary costs associated with a CF birth.

The technology and cost of DNA diagnostic testing for a CF mutation are changing rapidly. At present, the cost of DNA diagnostic testing for CF is between \$50 and \$150 per test, testing for between 6 and 72 CF mutations. Rapid progress is being made in cost of testing, however, because of improvements in instrumentation. These costs will likely decline and the number of mutations screened will quickly increase.

In terms of the cost of prenatal testing, the costs of informed consent procedures, educational and counseling services, associated administrative costs, and so forth must be added to the laboratory testing costs per se. These costs will vary as a function of the level of various educational and counseling services accompanying the testing according to evolving professional standards for genetic testing procedures.

Regarding cost savings from neonatal testing, currently no definitive data demonstrate medical benefit and cost savings associated with population-based neonatal screening. However, there is suggestive evidence that differences in height, weight, and nutrition of youngsters with CF are a function of whether they had neonatal screening and early diagnoses. These may well translate into future health outcomes and treatment savings, but the magnitude of such benefits is not known.

Broader assessment of the costs of a voluntary, broad-based prenatal screening program depends on variables such as the number of individuals deciding to participate in the test, the incidence of CF carriers in the population involved, the testing method (e.g., sequential or couple-based), the proportion of couples with an affected fetus who choose to terminate the pregnancy, and the number of children the couples wish to have. Although assumptions about these variables differed, studies showed that the cost per identified CF fetus averted ranged from \$250,000 to \$1,250,000 for a Caucasian population of Northern European ancestry. Estimates on the high end of this range come down substantially if one considers couples who plan to have more than one child or if identified carriers inform siblings and other relatives.

A broad educational effort is essential to create a level of genetic literacy in the population and among health care professionals that will allow individuals to utilize genetic and other information in making important life decisions. An estimate of the costs of this effort is not available.

3. Should Cystic Fibrosis Carrier Testing Be Offered to: (1) Individuals with a Family History of Cystic Fibrosis, (2) Adults in the Preconception or Prenatal Period, and/or (3) the General Population?

The first two sections of this report summarized the knowledge base for the recommendations that follow. Objectives for CF testing and reasons for and against testing are different for each population, but in all cases individuals' acceptance of testing must be entirely voluntary. Each population is considered separately.

1. *Individuals with a family history of CF and partners of those with CF should be offered genetic testing.* As a group, individuals with a family history have relatively high

frequencies of mutations in the CFTR gene. Members of this group have increased awareness of their risk of being carriers, as well as increased familiarity with the disease and its impact on the family. Testing can be helpful with regard to reproductive decisionmaking and informative regarding family health.

2. *CF genetic testing should be offered to the prenatal population and couples currently planning a pregnancy, particularly those in high-risk populations.* Data indicate that a significant level of interest in CF testing exists in this group. Because this is a vulnerable population and because of the inherent time constraints, it is particularly important that they receive adequate and balanced information. The information includes, but is not limited to, sensitivity of the test, a description of the range of severity of the disease, and risks. The offer of testing should be made to enable couples who wish to avoid the birth of a child with CF to do so, without influencing those who do not. Care should be taken to ensure that the decision to have testing is completely voluntary.
3. *CF testing for the general population is not advocated.* Given the low incidence and prevalence of CF and the demonstrable lack of interest in the general population, there is little justification for testing.
 - *Routine genetic screening for CF in newborns is not advocated, based on available data.* Studies have not provided sufficient evidence that identifying CF patients earlier than the current average age of diagnosis improves outcomes. The panel recommends that studies of CFTR screening in newborns be developed to provide a foundation for assessment of benefits of early therapy.
 - *Education and informed consent.* Genetic testing for CF should begin with education concerning CF. It should be clear that the patient has received the material and has had an opportunity for questions to be answered before testing is undertaken. Development of model educational and consent forms for genetic testing, as well as education programs for providers, is encouraged. All persons undergoing genetic testing should give written informed consent for the test, receive culturally sensitive educational materials, and demonstrate an understanding of the test and test results.

It is essential that the offering of CF carrier testing be phased in over a period of time to ensure that adequate education and appropriate genetic testing and counseling services are available to all persons being tested.

Genetic testing and counseling for CF in the populations identified by the panel's recommendations should be eligible for payment by insurers.

4. **What Are the Optimal Practices for Cystic Fibrosis Genetic Testing (Setting, Timing, and the Practices of Education, Consent, and Counseling)?**

The goal of genetic testing for CF is to provide individuals with information that will permit them to make informed reproductive and other decisions. Testing is of benefit only if there is access to the necessary comprehensive health services and resources that ensue from case/carrier detection. Components of a testing program should include education, counseling, and the use of medical facilities to improve health outcomes.

The setting must provide access for provision of comprehensive services. Whether it is based in a medical center or in a primary care setting, a professional interdisciplinary team should address the individual's genetic, medical, emotional, and reproductive health needs. The services should not be administered in isolation, but in association with tertiary care centers.

The complexity of DNA diagnostic data and the vast number of mutations in CF mandate sophisticated laboratory capability (or access to it) as an integral component. Laboratories providing molecular diagnostic capability should utilize tests that achieve a mutation detection rate of approximately 90 percent or better for Caucasians or a detection rate for African-Americans, Asian-Americans, Hispanics, Ashkenazi Jews, Native Americans, and others comparable to that available at present.

Timing for Testing Depends on Targeted Group

- In adults with a positive family history of CF, genetic testing should be provided at any time requested.
- Newborn siblings of patients with CF as well as other siblings who exhibit atypical symptoms should be tested. However, testing of minors for the purpose of identifying carrier status is not recommended.
- Carrier detection in pregnant couples with a family history of CF should be provided in an expeditious manner. Similarly, the request by a couple with known carrier status for prenatal diagnosis must be addressed promptly to facilitate access to all needed services so as to provide an optimal opportunity to make an informed decision.
- Couples in the prenatal population (i.e., those not in a high-risk group) should be offered the opportunity for carrier detection as early as possible to provide them time to consider the full range of informed reproductive decisions.
- The rationale for offering testing to couples currently planning a pregnancy is predicated on timely provision of balanced, accurate information about CF, including natural history of the disease, relative frequency in different ethnic and racial groups, variability of disease manifestation, and availability of highly sensitive and specific tests to determine carrier status.
- Although most males who have CF are sterile, partners of persons with CF should be tested on request for carrier status. The highest practical level of sensitivity of the DNA test should be used to maximize detection of at-risk couples.

Education

Genetic testing should be provided in response to the needs of patients. Thus, programs must provide information relating to genetics in general such as basic inheritance patterns, variable nature of disease expression, risk of occurrence, and diagnostic and therapeutic options. In the case of CF testing programs, balanced information should be presented and regularly updated. The elements that must be included are:

1. Natural history of the disease
2. Range of severity
3. Improvement in survival rates
4. Quality of life for patients and families
5. Full range of therapeutic modalities
6. Reproductive options, including adoption, use of artificial reproductive modalities, and continuation or termination of pregnancy

Educating patients and families can be accomplished by utilizing a wide variety of printed materials and media, including videos and interactive on-line systems. At present, information

content is presented in a variable manner. It is recommended that effort be directed to develop model information that highlights the positive as well as the negative aspects of living with CF; using input from people living with the disease, their families, and members from diverse racial/ethnic groups.

Every attempt should be made to ascertain the level of understanding and cultural background of the person being tested. Followup assessment to determine retention of knowledge is an essential ingredient of any educational program.

Informed Consent

To ensure informed choice, it is imperative that the informed consent process demonstrate that the individual has fully understood the multiple options and implications that ensue from genetic testing. It is also important to ensure that those who decline to be tested do so knowledgeably, although this is typically not documented. Informed consent must include a clear description of the disease, of the limitations of the genetic testing methods, and of the voluntary participation of the individual giving consent. Individuals must be assured that although every effort will be made to ensure the confidentiality of their medical and genetic data, absolute confidentiality cannot be guaranteed.

Counseling

Provision of accurate genetic counseling, particularly when the results are provided to the patient or when the intervention strategies are discussed, is essential. The implications of genetic testing, its limitations and strengths, and the risks of ensuing potential therapies and interventions mandate that individuals knowledgeable in genetics provide these services. The counseling skills required must combine respect for a patient's right to make an autonomous decision with an appropriate level of support to facilitate the decisionmaking process.

Any strategy attempting to provide these services to the public carries with it a responsibility to enhance the educational process for physicians and other health care providers. Rapid changes in the methodology of molecular diagnosis, and therapeutic options that result from them, mandate continuing education and involvement of genetic specialists in the process of translating these developments into practical and beneficial terms. CF centers should make counseling available to minor siblings who often have a need for information that goes unaddressed.

Nondiscrimination

Pivotal to individual autonomy is the guarantee that genetic data not be used for discrimination with reference to insurability, employment and educational opportunities, and social stigmatization.

Federal and State statutes currently in place to address nondiscriminatory practices against any carrier, person with a genetic disorder, or family member need to be enforced. However, these laws provide limited protection from discriminatory practices. Additional Federal and State statutes are needed to broaden protection from harm based on genetic status from educational, health care, and other organizations that may impact on and restrict immediate and long-term opportunities. Special attention to expand the understanding and awareness of the legal, insurance, health care, and educational professions about discriminatory practices should be undertaken.

In spite of laws that are put into place to protect people from external discrimination, less visible or more subtle harm may occur. For example, families may perceive differently a member found to be a carrier or found to be affected with a genetic disorder. These families may marginalize or ostracize the identified person. No laws can be passed to provide protection from this practice; however, future research is needed to understand the parameters of this problem and the moderating impact of education and counseling.

5. What Should Be the Future Directions for Research Relevant to Genetic Testing for Cystic Fibrosis and, More Broadly, for Research and Health Policies Related to Genetic Testing?

- As treatment options and screening technologies change, what are the impacts on medical costs, ancillary costs, and quality of life associated with CF? What are the cost-effective approaches to treatment and screening in different settings?
- What is the actual incidence of discrimination and stigmatization with respect to carriers, persons with genetic disorders, and their families? How does fear or anticipation of discrimination impact decisionmaking by some persons with identified genetic disorders?
- What is the most effective mechanism to educate health professionals about the current state of genetic disorders, genetic testing, and management of genetic disorders?
- What are effective educational strategies to educate the public and specific populations about genetics and genetic testing?
- What are patients' expectations of pretest education, genetic reproductive risk counseling, genetic evaluations, and transmittal of test results?
- Do early diagnosis and treatment of newborn infants with CF modify the morbidity as indicated by pulmonary function tests, maturation status, rates of infection, hospitalization, and mortality rates?
- A variety of screening strategies have been used in various studies (e.g., sequential versus couple screening). A systematic literature review should be undertaken, and, if warranted, a randomized controlled trial should be initiated to assess the relative merits of these strategies.
- Certain specific mutations appear to result in limited phenotypes, such as CBAVD. A goal of future research should be to continue to identify additional mutations, modifier genes, and environmental factors, and correlate these with the phenotype.
- Because CF is characterized by multiple mutations of the CFTR gene, this disease would be the prototype for the assessment of multiple methodologies to define numerous allelic mutations of a large gene.
- The optimal system for delivery of genetic services in rural and nonacademic settings should be studied.
- What are long-term effects of pregnancy termination or continuation on high-risk couples?

Conclusions and Recommendations

- Active research should continue on improved treatments for people with CF, enhanced molecular diagnosis of CF, and better understanding of the pathophysiology of CF.
- Over the past two decades, aggressive management of the pulmonary manifestations of CF and new treatment modalities have resulted in much longer survival.
- More than 90 percent of CF mutations can be identified in certain populations. Although generally good correlations exist between certain CF mutations and pancreatic status, it is known that CF mutations are not robust predictors of severity of disease and longevity.
- The goal of genetic testing is to provide individuals with information that will permit them to make informed decisions.
- CF genetic testing should be offered to adults with a positive family history of CF, to partners of people with CF, to couples currently planning a pregnancy, and to couples seeking prenatal testing.
- Comprehensive educational programs are recommended, utilizing a variety of media, for health care professionals and the public.
- Counseling services must be accurate and provide balanced information to afford individuals the opportunity to make autonomous decisions. Every attempt should be made to protect individual rights and genetic and medical privacy rights and to prevent discrimination and stigmatization.
- Access to genetic testing in the prenatal setting enhances the ability of couples to make reproductive choices, as shown by their interest in and use of the information they gain. The cost is reasonable in relation to the benefits obtained.
- Offering CF genetic testing to the general population or to newborn infants is not recommended.
- Genetic testing for many additional conditions will be available in the future. Some of the principles considered for CF genetic testing might well have broader application.
- It is essential that the offering of CF carrier testing be phased in over a period of time in order to ensure that adequate education and appropriate genetic testing and counseling services are available to all persons being tested.

Consensus Development Panel

R. Rodney Howell, M.D.
Conference and Panel Chairperson
Professor and Chairman
Department of Pediatrics
School of Medicine
University of Miami
Miami, Florida

Ingrid Borecki, Ph.D.
Research Associate Professor
Division of Biostatistics
School of Medicine
Washington University
St. Louis, Missouri

Mary E. Davidson, M.S.W., L.C.S.W.-C.
Executive Director
Alliance of Genetic Support Groups
Chevy Chase, Maryland

Ezra C. Davidson, Jr., M.D.
Professor
Department of Obstetrics and Gynecology
King Drew Medical Center and Charles R.
Drew University of Medicine and Science
Los Angeles, California

James P. Evans, M.D., Ph.D.
Clinical Associate Professor,
Internal Medicine
University of North Carolina at Chapel Hill
Internist and Geneticist
Carolina Permanente Medical Group
Durham, North Carolina

Bonnie J. Flick, M.D.
Assistant Professor
Departments of Pediatrics and Psychiatry
University of Utah Health Sciences Center
Salt Lake City, Utah

Bradford H. Gray, Ph.D.
Director
Division of Health and Science Policy
New York Academy of Medicine
New York, New York

Mark S. Kamlet, Ph.D.
Dean and H. John Heinz III Professor of
Economics and Public Policy
H. John Heinz School of Public Policy
and Management
Carnegie Mellon University
Pittsburgh, Pennsylvania

Elizabeth R. McAnarney, M.D.
Professor and Chair
Department of Pediatrics
University of Rochester School of Medicine
Rochester, New York

Vicki Michel, M.A., J.D.
Consultant and Mediator in Bioethics and Law
Los Angeles, California
Adjunct Professor
Loyola Law School
Los Angeles, California

Robb E. Moses, M.D.
Chair
Department of Molecular and
Medical Genetics
Oregon Health Sciences University
Portland, Oregon

Owen M. Rennert, M.D.
Professor and Chairperson
Department of Pediatrics
Georgetown University Medical
Center
Washington, DC

Stephanie C. Smith, M.S.
Genetic Associate
Genetics Services Coordinator
Division of Medical Genetics
Department of Preventive Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Janet K. Williams, Ph.D., R.N.
Associate Professor
College of Nursing
University of Iowa
Iowa City, Iowa

Speakers

David A. Asch, M.D., M.B.A.
"Carrier Screening for Cystic Fibrosis: Costs
and Clinical Outcomes"
Assistant Professor of Medicine
Senior Fellow, Leonard Davis Institute of
Health Economics
Department of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Arthur L. Beaudet, M.D.
"Making the Case for Offering Cystic Fibrosis
Carrier Testing on a Population Basis"
Henry and Emma Meyer Professor and
Acting Chairman
Department of Molecular and Human Genetics
Baylor College of Medicine
Investigator
Howard Hughes Medical Institute
Houston, Texas

Barbara A. Bernhardt, M.S.
"Offering Cystic Fibrosis Carrier Screening to
an HMO Population: Utilization,
Knowledge,
and Factors Influencing the Decision To
Be Tested"
Assistant Professor, Genetic Counselor
Department of Pediatrics
Division of Genetics and Public Policy Studies
School of Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland

Thomas F. Boat, M.D.
"Cystic Fibrosis in the Post-CFTR Era"
Professor and Chair
Department of Pediatrics
University of Cincinnati
Director
Children's Hospital Research Foundation
Children's Hospital Medical Center
Cincinnati, Ohio

Preston W. Campbell III, M.D.
"Cystic Fibrosis Therapy"
Associate Professor
Department of Pediatrics
Vanderbilt University
Nashville, Tennessee

Garry R. Cutting, M.D.
"Genetic Epidemiology and
Genotype/Phenotype Correlations"
Associate Professor of Pediatrics and Medicine
Department of Pediatrics
Johns Hopkins University School of Medicine
Baltimore, Maryland

Richard A. Doherty, M.D.
"Prenatal Couple Screening for Cystic Fibrosis
in Primary Care Settings"
Director
Southern Maine Regional Genetics Program
Department of Genetics
Foundation for Blood Research
Scarborough, Maine

Christine M. Eng, M.D.
"Prenatal Genetic Carrier Screening:
Experience With Multiple Option Screening
in the Ashkenazi Jewish Population"
Assistant Professor
Department of Human Genetics
Mount Sinai School of Medicine
New York, New York

Joanna H. Fanos, Ph.D.
"Carrier Testing for Adult Cystic Fibrosis
Siblings: The Importance of Not Knowing"
Senior Scientist
Departments of Pediatrics, Medicine,
and Psychiatry
California Pacific Medical Center
Research Institute
San Francisco, California

Theresa A. Grebe, M.D.
"Cystic Fibrosis Among Native Americans of
the Southwest"
Assistant Professor of Clinical Pediatrics
Division of Medical and Molecular Genetics
Department of Pediatrics
University of Arizona College of Medicine
Phoenix, Arizona

Wayne W. Grody, M.D., Ph.D.
"Cystic Fibrosis Mutation Screening and
Counseling"
Associate Professor
Divisions of Medical Genetics and
Molecular Pathology
Director, Diagnostic Molecular Pathology
Laboratory
Departments of Pathology, Laboratory
Medicine, and Pediatrics
UCLA School of Medicine
Los Angeles, California

Neil A. Holtzman, M.D., M.P.H.
"A Standard of Care for Cystic Fibrosis
Carrier Screening: Satisfying Equity and
Autonomy"
Director
Genetics and Public Policy Studies
Department of Pediatrics
The Johns Hopkins Medical Institutions
Baltimore, Maryland

Katherine W. Klinger, Ph.D.
"Genetic Testing Technologies"
Vice President, Science
Genzyme Genetics
Framingham, Massachusetts

Tracy Lieu, M.D., M.P.H.
"Cost-Effectiveness of Prenatal Carrier
Screening for Cystic Fibrosis"
Physician Investigator
Division of Research
Kaiser Permanente of Northern California
Oakland, California

Theresa M. Marteau, Ph.D.
"Cystic Fibrosis Carrier Testing in the
Population: A U.K. Perspective"
Professor of Health Psychology
Director
Psychology and Genetics Research Group
United Medical and Dental Schools of Guy's
and St. Thomas's (UMDS)
University of London
London, England

John A. Phillips III, M.D.
"Efficacy of Education for and Interest in
Population-Based Cystic Fibrosis Carrier
Screening"
David T. Karzon Professor of Pediatrics
and Professor of Biochemistry
Department of Pediatrics
Vanderbilt University School of Medicine
Nashville, Tennessee

Michael J. Rock, M.D.
"Newborn Screening"
Assistant Professor of Pediatrics
Division of Pediatric Pulmonology
Department of Pediatrics
University of Wisconsin
Madison, Wisconsin

Peter T. Rowley, M.D.
"Prenatal Cystic Fibrosis Carrier Population
Screening: Lessons from a Regional Trial"
"Economic Evaluation of Cystic Fibrosis
Carrier Population Screening"
Professor of Medicine, Pediatrics, Genetics
Division of Genetics
University of Rochester School of Medicine
Rochester, New York

James R. Sorenson, Ph.D.
"Carrier Testing Among First, Second, and
Third Degree Relatives of Cystic Fibrosis
Patients"
Professor
Department of Health Behavior and Education
School of Public Health
University of North Carolina
Chapel Hill, North Carolina

Benjamin S. Wilfond, M.D.
"Normative Issues in Developing Public
Policy for Cystic Fibrosis Carrier Testing"
Assistant Professor
Department of Pediatrics
University of Arizona Health Science Center
Tucson, Arizona

David R. Witt, M.D.
"Prenatal Cystic Fibrosis Heterozygote
Screening of 5,161 Women in a Large HMO"
Chief
Genetics Department
Kaiser Permanente Medical Group
San Jose, California

Planning Committee

Elizabeth Thomson, M.S., R.N.
Chairperson
Assistant Director, Clinical Genetics Research
National Human Genome Research Institute
National Institutes of Health
Bethesda, Maryland

Susan Banks-Schlegel, Ph.D.
Senior Scientific Adviser
Airway Biology and Diseases Program
Division of Lung Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

Joy Boyer
Program Analyst
Ethical, Legal, and Social Implications Office
National Human Genome Research Institute
National Institutes of Health
Bethesda, Maryland

Elsa A. Bray
Program Analyst
Office of Medical Applications of Research
National Institutes of Health
Bethesda, Maryland

Sharon A. Durham
Public Affairs Specialist
Office of Policy Coordination
National Human Genome Research Institute
National Institutes of Health
Bethesda, MD

John H. Ferguson, M.D.
Director
Office of Medical Applications of Research
National Institutes of Health
Bethesda, Maryland

Judith Fradkin, M.D.
Chief, Endocrinology and Metabolic Diseases
Program Branch
National Institute of Diabetes and Digestive
and Kidney Diseases
National Institutes of Health
Bethesda, Maryland

Steven C. Groft, Pharm.D.
Director, Office of Rare Diseases
Office of the Director
National Institutes of Health
Bethesda, Maryland

William H. Hall
Director of Communications
Office of Medical Applications of Research
National Institutes of Health
Bethesda, Maryland

R. Rodney Howell, M.D.
Conference and Panel Chairperson
Professor and Chairman
Department of Pediatrics
School of Medicine
University of Miami
Miami, Florida

Elke Jordan, Ph.D.
Deputy Director
Office of the Director
National Human Genome Research Institute
National Institutes of Health
Bethesda, Maryland

David Lanier, M.D.
Medical Officer
Center for Primary Care Research
Agency for Health Care Policy and Research
Rockville, Maryland

June Lunney, Ph.D., R.N.
National Institute of Nursing Research
National Institutes of Health
Bethesda, Maryland

Monique K. Mansoura, Ph.D.
Postdoctoral Fellow
Laboratory of Gene Transfer
National Human Genome Research Institute
National Institutes of Health
Bethesda, Maryland

Eric Meslin, Ph.D.
Chief
Ethical, Legal, and Social Implications Office
National Human Genome Research Institute
National Institutes of Health
Bethesda, MD

Steven O. Moldin, Ph.D.
Chief, Genetics Research Program
National Institute of Mental Health
National Institutes of Health
Rockville, Maryland

Robert F. Murray, Jr., M.D.
Professor and Chief
Division of Medical Genetics
Howard University College of Medicine
Washington, DC

Melissa A. Rosenfeld, M.D.
Acting Chief
Vector Development Section
Laboratory of Gene Transfer
National Human Genome Research Institute
National Institutes of Health
Bethesda, Maryland

Karen Rothenberg, J.D.
Marjorie Cook Professor of Law
Director, Law and Health Care Program
University of Maryland
Baltimore, Maryland

Charles R. Sherman, Ph.D.
Deputy Director
Office of Medical Applications of Research
National Institutes of Health
Bethesda, Maryland

Ellen Sidransky, M.D.
Chief, Unit on Clinical Genetics
Clinical Neuroscience Branch
National Institute of Mental Health
National Institutes of Health
Bethesda, Maryland

Hilary Sigmon, Ph.D., R.N.
National Institute of Nursing Research
National Institutes of Health
Bethesda, Maryland

Judy A. Small, Ph.D.
Health Science Administrator
National Institute of Neurological Disorders
and Stroke
National Institutes of Health
Bethesda, Maryland

Suzanne P. Tomlinson, J.D.
Cystic Fibrosis Consumer
Alexandria, Virginia

Judith M. Whalen
Associate Director for Science Policy Analysis
and Communication
National Institute of Child Health and Human
Development
National Institutes of Health
Bethesda, Maryland

Benjamin S. Wilfond, M.D.
Assistant Professor
Department of Pediatrics
University of Arizona Health Science Center
Tucson, Arizona

Conference Sponsors

Office of Medical Applications of Research, NIH

John H. Ferguson, M.D.
Director

National Human Genome Research Institute

Francis S. Collins, M.D.
Director

Conference Cosponsors

Agency for Health Care Policy and Research

John Eisenberg, M.B.A, M.D.
Administrator

Centers for Disease Control and Prevention

David Satcher, M.D,
Director

National Institute of Child Health and Human Development

Duane F. Alexander, M.D.
Director

National Institute of Diabetes and Digestive and Kidney Diseases

Phillip Gorden, M.D.
Director

National Heart, Lung, and Blood Institute

Claude Lenfant, M.D.
Director

National Institute of Mental Health

Steven E. Hyman, M.D.
Director

National Institute of Nursing Research

Patricia A. Grady, R.N., Ph.D.
Director

NIH Office of Rare Diseases

Steven C. Groft, Pharm.D.
Director

NIH Office of Research on Women's Health

Vivian W. Pinn, M.D.
Director

Bibliography

Asch DA, Hershey JC, Pauly MV, Patton JP, Jedrzejewski MK, Mennuti MT. Genetic screening for reproductive planning: methodologic and conceptual issues in policy analysis. *Am J Public Health* 1996;86:684-90.

Asch DA, Mennuti MT. Evolving policy questions in the use of genetic tests. *IEEE Technol Soc* 1996;15(4):4-11.

Asch DA, Patton JP, Hershey JC, Mennuti MT. Reporting the results of cystic fibrosis carrier screening. *Am J Obstet Gynecol* 1993;168:1-6.

Axworthy D, Brock DJH, Bobrow M, Marteau TM. Psychological impact of population-based carrier testing for cystic fibrosis: three year follow-up. *Lancet* 1996;347:1443-6.

Beaudet AL. Invited editorial: carrier screening for cystic fibrosis. *Am J Hum Genet* 1990;47:603-5.

Bekker H, Modell M, Dennis G, Silver A, Mathew C, Bobrow M, Marteau TM. Uptake of cystic fibrosis carrier testing in primary care: supply push or demand pull? *BMJ* 1993;306:1584-6.

Bernhardt BB, Chase GA, Faden RR, Geller G, Hofman KJ, Tambor ES, Holtzman NA. Educating patients about cystic fibrosis carrier screening in a primary care setting. *Arch Fam Med* 1996;5:336-40.

Botkin JR. Fetal privacy and confidentiality. *Hastings Center Report* 1995;25:32-9.

Brock DJH. Prenatal screening for cystic fibrosis: 5 years' experience reviewed. *Lancet* 1996;347:148-50.

Callanan N, Bloom D, Sorenson J, DeVellis B, Cheuvront B. CF carrier testing: experience of relatives. *J Gen Couns* 1995;4(2):83-95.

Chase GA, Bernhardt BA, Faden RR, Geller G, Tambor ES, Holtzman NA (1995) Confirmation of a finding on tolerance for test uncertainty (TTU) in cystic fibrosis carrier screening. *Am J Hum Genet* 57(4 Suppl):A29.

Cheuvront B, Sorenson J, Callanan N, Stearns S, DeVellis B. Psychosocial and educational outcomes associated with home and clinic based pretest education and cystic fibrosis carrier testing among a population of at risk relatives. Unpublished manuscript.

Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. *N Engl J Med* 1995;332:1475-80.

Clayton EW, Hannig VH, Pfothenhauer JP, Parker RA, Campbell PW III, Phillips JA III. Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. *Am J Hum Genet* 1996;58:617-27.

Clayton EW, Hannig VH, Pfothenhauer JP, Parker RA, Campbell PW III, Phillips JA III. Teaching about cystic fibrosis carrier screening by using written and video information. *Am J Hum Genet* 1995;57:171-81.

Congress of the United States, Office of Technology Assessment. Cystic fibrosis and DNA tests: implications of carrier screening, OTA-BA-532. Washington, DC: U.S. Government Printing Office; August 1992.

Cotton RGH. Current methods of mutation detection. *Mutat Res* 1993;285:125-44.

Cystic Fibrosis Genetic Analysis Consortium. Population variation of common cystic fibrosis mutations. *Hum Mutat* 1994;4:167-77.

Davis PB, Drumm M, Konstan MW. Cystic fibrosis. *Am J Respir Crit Care Med* 1996;154:1229-56.

Doherty RA, Bradley LA, Haddow JE. Prenatal screening for cystic fibrosis: an updated perspective. *Am J Obstet Gyn* 1997;176:268-70.

Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Haddow JE. Couple-based prenatal screening for cystic fibrosis in primary care settings. *Prenat Diagn* 1996;16:397-404.

Doksum T, Bernhardt BA. Population-based carrier screening for cystic fibrosis. *Clin Obstet Gynec* 1996;39:763-71.

Eng, Christine. Prenatal genetic carrier screening: experience with triple disease screening in the Ashkenazi Jewish population. Unpublished manuscript.

Fang CY, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Bass HN, Crandall BF, Grody WW. Genetic carrier screening for cystic fibrosis in pregnant women: applying and extending the health belief model. *Women's Health*. In press.

Fanos JH. Developmental tasks of childhood and adolescence: implications for genetic testing. *Am J Med Genet*. In press.

Fanos, JH. Sibling loss. Mahwah, NJ: Lawrence Erlbaum Associates; 1996.

Fanos JH, Johnson JP. Barriers to carrier testing for adult siblings: the importance of not knowing. *Am J Med Genet* 1995;59:85-91.

Fanos JH, Johnson JP. Perception of carrier status by cystic fibrosis siblings. *Am J Hum Genet* 1995;57:431-8.

Farrell PM, Aronson RA, Hoffman G, Laessig RH. Newborn screening for cystic fibrosis in Wisconsin: first application of population-based molecular genetics testing. *Wis Med J* 1994;93:415-21.

Farrell PM, Mischler EH. Newborn screening for cystic fibrosis. *Adv Pediatr* 1992;39:31-64.

Grebe TA, Doane WW, Richter SF, Clericuzio C, Norman RA, Seltzer WK, Rhodes SN, et al. Mutation analysis of the cystic fibrosis transmembrane regulator gene in native American populations of the southwest. *Am J Hum Genet* 1992;51:736-40.

Gregg RG, Simantel A, Farrell PM, Kosciuk R, Kosorok MR, Laxova A, Laessig R, Hoffman G, Hassemer D, Mischler EH, Splaingard M. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. *Pediatrics*. In press.

Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. *Am J Hum Genet* 1993;52:616-26.

Grody WW, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Fang CY, Cantor RM, Novak JM, Bass HN, Crandall BF. PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. *Am J Hum Genet*. In press.

Grody WW, Kronquist KE, Lee EU, Edmond J, Rome LH. PCR-based cystic fibrosis carrier screening in a first-year medical student biochemistry laboratory. *Am J Hum Genet* 1993;53:1352-5.

Hacia JG, Brody LC, Chee MS, Fodor SPA, Collins FS. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-color fluorescence analysis. *Nat Genet* 1996;14:441-7.

Haddow JE, et al. Similarities in women's decision-making in the U.S. and U.K. during prenatal screening for Down's syndrome. *Prenat Diagn* 1996;16:1161-2.

Hamosh A, Fitzsimmons SC, Macek MJ, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in African-Americans and Caucasians. *J Pediatr*. In press.

Lemna WK, Feldman GL, Kerem Bat-sheva, Fernbach SD, Zevkovich EP, O'Brien WE, Riordan JR, Collins FS, Tsui L-C, Beaudet AL. Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. *N Engl J Med* 1990;322:291-6.

Levenkron JC, Loader S, Rowley PT. Carrier screening for cystic fibrosis: test acceptance and one year follow-up. *Am J Med Genet*. In press.

Lieu TA, Watson SE, Washington AE. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. *Obstet Gynecol* 1994;84:903-12.

Loader S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr, Rowley PT. Cystic fibrosis carrier population screening in the primary care setting. *Am J Hum Genet* 1996;59:234-47.

Marteau TM. Psychological consequences of cystic fibrosis heterozygote screening. In: Dodge J, Widdicombe J, Brock D, editors. *Current topics in cystic fibrosis*, Vol. III. John Wiley & Sons; 1993. p. 165-80.

Marteau TM, Dundas R, Axworthy D. Long term cognitive and emotional impact of genetic testing for carriers of cystic fibrosis: the effects of gender and test result. *Health Psychol* 1997;16:51-62.

Mercier B, Raguénès O, Estivill X, Morral N, Kaplan GC, McClure M, Grebe TA, et al. Complete detection of mutations in cystic fibrosis of Native American origin. *Hum Genet* 1994;94:629-32.

Myers MF, Bernhardt BA, Tambor ES, Holtzman NA. Involving consumers in the development of an educational program for cystic fibrosis carrier screening *Am J Hum Genet* 1994;54:719-26.

- Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. *N Engl J Med* 1996;335(3):179-88.
- Rosenfeld MA, Collins FS. Gene therapy for cystic fibrosis. *Chest* 1996;109:241-52.
- Rowley PT, Loader S, Levenkron JC. Cystic fibrosis carrier population screening: a review. Unpublished manuscript.
- Rowley PT, Loader S, Levenkron JC, Kaplan RM. Cystic fibrosis carrier population screening: an economic evaluation. Unpublished manuscript.
- Rowley PT, Loader S, Levenkron JC, Phelps CE. Cystic fibrosis carrier screening: knowledge and attitudes of prenatal care providers. *Am J Prev Med* 1993;9:261-6.
- Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. *Nature Genet* 1996;12:280-7.
- Shuber AP, Michalowsky LA, Nass GS, Skoletsky J, Hire LM, Kotsopoulos SK, Phipps MF, Barberio DM, Klinger KW. High throughput parallel analysis of hundreds of patient samples for more than 100 mutations in multiple disease genes. *Hum Mol Genet* 1997;6(3):337-47.
- Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. *Cell* 1996;85:231-6.
- Sorenson J, Cheuvront B, Bruning A, Talton S, DeVellis B, Koch G, Callanan N, Fernald G. Proband and parent assistance in identifying relatives for cystic fibrosis carrier testing. *Am J Med Genet* 1996;63:419-25.
- Sorenson J, Cheuvront B, DeVellis B, Callanan N, Silverman L, Koch G, Sharp T, Fernald G. Acceptance of home and clinic based cystic fibrosis carrier education and testing by first, second, and third degree relatives of cystic fibrosis patients. *Am J Med Genet*. In press.
- Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, Holtzman NA. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. *Am J Hum Genet* 1994;55:626-37.
- Tatsugawa Z, Fox MA, Fang C, Novak JM, Cantor R, Bass HN, Dunkel-Schetter C, Crandall BF, Grody WW. Education and testing strategy for large-scale cystic fibrosis carrier screening. *J Genet Couns* 1994;3:279-89.
- Wald NJ. Couple screening for cystic fibrosis. *Lancet* 1991;338:1318-9.
- Welsh MJ, Tsui L-C, Boat TF, Beaudet AL. Cystic fibrosis. In: *The metabolic and molecular bases of inherited disease*, 7th ed. New York: McGraw-Hill; 1995. p. 3799-876.
- Wilfond BS, Fost N. The cystic fibrosis gene: medical and social implications for heterozygote detection. *JAMA* 1990;263:2777-83.
- Wilfond BS, Fost N. The introduction of cystic fibrosis carrier screening into clinical practice: policy considerations. *Milbank Quarterly* 1992;70:629-59.

Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies: Lessons from cystic fibrosis. *JAMA* 1993;270:2948-54.

Witt DR, Schaefer C, Hallam P, Wi S, Blumberg B, Fishbach A, Holtzman J, Kornfeld S, Lee R, Nemzer L, Palmer R. Cystic fibrosis heterozygote screening in 5,161 pregnant women. *Am J Hum Genet* 1996;58:823-35.

ABOUT THE NIH CONSENSUS DEVELOPMENT PROGRAM

NIH Consensus Development Conferences are convened to evaluate available scientific information and resolve safety and efficacy issues related to a biomedical technology. The resultant NIH Consensus Statements are intended to advance understanding of the technology or issue in question and to be useful to health professionals and the public.

NIH Consensus Statements are prepared by a nonadvocate, non-Federal panel of experts, based on (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session, (2) questions and statements from conference attendees during open discussion periods that are part of the public session, and (3) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and is not a policy statement of the NIH or the Federal Government.

Statement Availability

Preparation and distribution of this statement is the responsibility of the Office of Medical Applications of Research of the National Institutes of Health. Free copies of this statement and bibliographies prepared by the National Library of Medicine are available from the Office of Medical Applications of Research, National Institutes of Health, or the NIH Consensus Program Information Center by 24-hour voice mail. In addition, free copies of all other available NIH Consensus Statements and NIH Technology Assessment Statements may be obtained from the following resources:

NIH Consensus Program Information Center
P.O. Box 2577
Kensington, MD 20891
Telephone: 1-888-NIH-CONSENSUS (888-644-2667)
Fax: (301) 816-2494

NIH Office of Medical Applications of Research
Federal Building, Room 618
7550 Wisconsin Avenue MSC 9120
Bethesda, MD 20892-9120

Internet

World Wide Web
<http://consensus.nih.gov>

FTP
<ftp://public.nlm.nih.gov/hstat/nihcdcs>

Gopher
<gopher://gopher.nih.gov/Health and Clinical Information>

Draft . . . Draft . . . Draft . . . Draft . . . Draft . . . Draft . . . Draft

Summary of Genetics Testing Information

April 15, 1997

Existing Proficiency Testing Programs (number of participants?)

American Society for Histocompatibility and Immunogenetics/College of American Pathologists

(ASHI/CAP) - HLA-B27 program (not really PT)

College of American Pathologists/American College of Medical Genetics (CAP/ACMG)

Microbiology - Nucleic Acid Amplification - includes *Mycobacterium tuberculosis*, *Chlamydia*, Herpes, HCV, and HIV-RNA by nucleic acid amplification

Cytogenetics - includes fluorescence in situ hybridization (FISH) - **270 Labs?**

Biochemical Genetics - includes testing amino acids, mucopolysaccharides, and organic acids in plasma, urine, or other material

Molecular Genetics - includes two programs for molecular testing

MGL-A - Factor V Leiden, Myotonic Dystrophy, DMD/Becker, and Cystic Fibrosis

MGL-B - Prader-Willi, Huntington Disease, Fragile X, and Friedreich Ataxia

New York State (clinical laboratory evaluation - not necessarily PT)

Genetic Testing - each analyte provides options for DNA analysis (direct and linkage) and biochemistry (enzymology and substrate quantitation) methods - subcategories are

Genetic Testing - DNA Based and Genetic Testing - Biochemistry

Adult Polycystic Kidney Disease

Duchenne Becker Muscular Dystrophy

Cystic Fibrosis

Duchenne Muscular Dystrophy

Fragile-X Syndrome (also included in cytogenetics)

Hemophilia A

Hemophilia B

Huntington Disease

Phenylketonuria

Retinoblastoma

Sickle Cell Anemia

Tay Sachs Disease

α - Thalassemia (Factor VIII Deficiency)

β - Thalassemia (Factor IX Deficiency)

Cytogenetics - karyotypic analysis of the metaphase chromosome complement of human cells

Cancer Cytogenetics - diagnostic evaluations of blood dyscrasias and the acquired cytogenetic changes of neoplasias

Prenatal Cytogenetics - includes amniotic fluid, chorionic villus, and fetal blood specimens

Limited Cytogenetics - cytogenetic tests exclusive of prenatal and cancer cytogenetics

Estimates of number of labs doing genetics testing in the U.S.

Molecular DNA testing - estimate 300 to 500 laboratories doing genetics testing

Cytogenetics laboratories - over 100 in U.S. (according to Andrew Chen)

- 344 as of April 1, 1997 according to HCFA

PROFICIENCY TESTING IN GENETICS LABORATORY DIAGNOSIS

Quality assurance programs are vital to achieving accurate and reliable laboratory test results, and one very useful tool in the quality assurance armamentarium is traditional proficiency testing. As the need for sound quality assurance programs for genetics testing has become apparent, the question as to whether or not it will be feasible to develop proficiency tests for molecular genetics has raised some concerns. CDC, FDA, and HCFA were asked to examine this question and especially to consider whether it might be possible to develop a test (or tests) to generically evaluate a laboratory's ability to perform accurate DNA testing.

The three agencies met by telephone on Wednesday, April 2, to discuss the question. The following summarizes our discussion:

1. Proficiency testing is only a part of quality assurance; there are other processes that help to assure accurate and reliable testing. We do have many kinds of tests for which there is no proficiency testing program.
2. Some kinds of genetic tests already have proficiency testing available through national programs. (For example, sickle hemoglobin (and other abnormal hemoglobins), cytogenetics, and some biochemical assays; a list of genetics-related PT programs that we have identified is attached.)
3. For DNA-related testing, two models were considered by the agencies. These were:

Focus on common genes of public health importance, and choose one or two for the development of a model proficiency testing or performance evaluation program. This approach would allow for a careful evaluation of the efficacy of PT in improving quality of DNA testing.

Attempt to devise a test or tests that could measure the ability of a laboratory to accurately identify genes or conduct DNA testing without being gene-specific. There was general agreement that, although there are many unanswered questions, some further examination of this idea is warranted and perhaps some pilot studies should be undertaken. Clearly no one has experience on which we can draw. A complicating factor is that there are many variations on how DNA testing is performed. One cautionary note mentioned was that past experience suggests that we may NOT be able to use a surrogate test to broadly evaluate laboratory performance.

From: Francis Collins/D [REDACTED]
Sent: Thursday, April 17, 1997 8:30 AM
To: Fakunding, Patricia
Subject: Revised materials for meeting of DHHS Working Group on Genetic Testing

Hi Patti, another one I couldn't read. Can you print out?
FC

CDC forwarded the attached materials yesterday afternoon. Based on a very quick visual scan, the changes appear to be in the second document which is a summary of the proficiency testing programs. BUT I could be wrong. So bring this version of both documents to the meeting tomorrow.

PROFTEST.GEN

Summary of Genetics Related Proficiency Testing Information

The following is a summary of the three existing genetics related proficiency testing programs of which we are aware. It has been estimated that there are 300 to 500 laboratories doing molecular DNA testing in the U. S. and according to HCFA there were 344 laboratories doing cytogenetics testing as of April 1, 1997.

American Society for Histocompatibility and Immunogenetics/College of American Pathologists (ASHI/CAP) -

HLA-B27 program (not really PT)

College of American Pathologists/American College of Medical Genetics (CAP/ACMG)

Microbiology - Nucleic Acid Amplification - includes *Mycobacterium tuberculosis*, *Chlamydia*, Herpes, HCV, and HIV-RNA by nucleic acid amplification

Cytogenetics - includes fluorescence in situ hybridization (FISH) - 270 Labs?

Biochemical Genetics - includes testing amino acids, mucopolysaccharides, and organic acids in plasma, urine, or other material

Molecular Genetics - includes two programs for molecular testing

MGL-A - Factor V Leiden, Myotonic Dystrophy, DMD/Becker, and Cystic Fibrosis

MGL-B - Prader-Willi, Huntington Disease, Fragile X, and Friedreich Ataxia

New York State (clinical laboratory evaluation - not necessarily PT)

Genetic Testing - each analyte provides options for DNA analysis (direct and linkage) and biochemistry (enzymology and substrate quantitation) methods - subcategories are Genetic Testing - DNA

Based and Genetic Testing - Biochemistry

Adult Polycystic Kidney Disease

Duchenne Becker Muscular Dystrophy

Cystic Fibrosis

Duchenne Muscular Dystrophy

Fragile-X Syndrome (also included in cytogenetics)

Hemophilia A

Hemophilia B

Huntington Disease

Phenylketonuria

Retinoblastoma

Sickle Cell Anemia

Tay Sachs Disease

α - Thalassemia (Factor VIII Deficiency)

β - Thalassemia (Factor IX Deficiency)

Cytogenetics - karyotypic analysis of the metaphase chromosome complement of human cells

Cancer Cytogenetics - diagnostic evaluations of blood dyscrasias and the acquired cytogenetic changes of neoplasias

Prenatal Cytogenetics - includes amniotic fluid, chorionic villus, and fetal blood specimens

Limited Cytogenetics - cytogenetic tests exclusive of prenatal and cancer cytogenetics

To: Francis Collins/DIR/NCHGR
cc:
From: ElkeJ @ [REDACTED] ("Jordan, Elke") @ INTERNET
Date: 04/18/97 01:20:33 PM
Subject: RE: Task Force on Genetic Testing

My committee has actually made good progress and has a proposal in the works for how the advisory committee might function. A key difference with the Task Force vision, is that the committee would consist of agency reps and outside people picked for their expertise and wisdom rather than for representing a particular stakeholder. The stakeholders would participate by attending the open meetings. We believe the dynamics of our version of the committee would work better and be less apt to deadlock. More details forthcoming shortly.

From: Francis
Co [REDACTED]
Sent: Thursday, April 17, 1997 5:43 PM
To: Jordan, Elke
Subject: RE: Task Force on Genetic Testing

I had it copied for you and your committee about a week ago -- I will ask Patti to make another for you in case it fell through the cracks. It would be really important for us to arrive at a reaction very soon.
FC

To: Francis Collins/D [REDACTED]
cc:
From: ElkeJ @ [REDACTED] @ INTERNET
Date: 04/17/97 06:07:54 PM
Subject: RE: Task Force on Genetic Testing

Do you have the document they are all commenting on? Is it in my box perhaps?

>-----
>**From:** Francis
>**C** [REDACTED]
>
>**Sent:** Wednesday, April 16, 1997 1:59 PM
>**To:** Elke Jordan; Kathey Hudson; Elizabeth Thomson; Jean Mckay; megans;
>**Robert Nussbaum /DIR/NCHGR**
>**Subject:** Task Force on Genetic Testing
>
>**To:** [REDACTED] @ INTERNET,
> [REDACTED]
> [REDACTED]
>**@**
>**INTERNET**
>**cc:** (bcc: [REDACTED])
>**From:** [REDACTED]
> [REDACTED]